Lipid nanoparticles for skin penetration enhancement—correlation to drug localization within the particle matrix as determined by fluorescence and parelectric spectroscopy

Nanoparticle Coated Submicron Emulsions: Sustained In-vitro Release and Improved Dermal Delivery of All-trans-retinol

“…Increased skin accumulation and simultaneously decreased permeation through the skin has been previously reported for a range of active agents from lipidic and polymeric nanoparticles (7,11,(50)(51)(52)(53)(54). The negligible permeation through the full-thickness porcine skin, in parallel to the significant increase in the skin retention of all-trans-retinol in this study confirmed the suitability of silica nanoparticlecoated submicron emulsions for topical delivery of this lipophilic molecule.…”

Nanostructured Lipid Carrier for Topical Application of N-Acetyl Glucosamine

“…The extremely sustained release might prevent the adequate accumulation of NAGA for the therapeutic efficacy, while too rapid drug release might cause the chance of NAGA systemic absorption. 28,29 This might interpret why we could not detect NAGA in the receiver phase of Franz diffusion cell in ex vivo experiments by excised rat skin. Furthermore, the very low UV molar absorptivity of NAGA did not provide enough sensitivity for determination of small amounts of passed NAGA through rat skin even with HPLC technique.…”

Improving Topical Non-Melanoma Skin Cancer Treatment: In vitro Efficacy of a Novel Guanosine-Analog Phosphonate

“…In order to study the effect of DMSO on skin penetration of an SLN-loaded drug, we loaded SLN with the probe Nile red (0.004%) using either glyceryl behenate (5 and 10%) without DMSO [26] or glyceryl behenate (5%) with DMSO (5%) for particle formulation as described above. Incorporation of Nile red into the lipid matrix was assured by parelectric spectroscopy.…”

“…Incorporation of Nile red into the lipid matrix was assured by parelectric spectroscopy. The penetration of Nile red-loaded SLN was studied in cryoconserved human female skin ex vivo (aged 39-54 years, n = 3 donors; with permission) according to a validated test protocol [26,27]. …”

“…The release rates of OxBu from formulations were studied as described [26], and the rate of OxBu release from formulations was calculated based on OxBu amounts in the acceptor fluid according to Higuchi [29]. …”